ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis

被引：4

作者：

Kim, Mi Na ^{[1
,2
]}

Lee, Jae Seung ^{[3
,4
]}

Lee, Hye Won ^{[3
,4
]}

Kim, Beom Kyung ^{[3
,4
]}

Park, Jun Yong ^{[3
,4
]}

Kim, Do Young ^{[3
,4
]}

Ahn, Sang Hoon ^{[3
,4
]}

Jang, Se Young ^{[5
]}

Tak, Won Young ^{[5
]}

Kweon, Young -Oh ^{[5
]}

Park, Soo Young ^{[5
]}

Kim, Seung Up ^{[3
,4
]}

机构：

[1] CHA Univ, Sch Med, CHA Bundang Med Ctr, Dept Internal Med,Div Gastroenterol, Seongnam, South Korea

[2] Clin & Translat Hepatol Lab, Seongnam, South Korea

[3] Yonsei Univ, Coll Med, Dept Internal Med, 50-1 Yonsei Ro, Seoul 03722, South Korea

[4] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea

[5] Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea

来源：

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 21卷 / 09期

基金：

新加坡国家研究基金会;

关键词：

Alanine Aminotransferase; Subcirrhotic Liver Stiffness; Hepatocellular Carcinoma; Chronic Hepatitis B; Cirrhosis; CHRONIC HEPATITIS-B; TENOFOVIR DISOPROXIL FUMARATE; HEPATOCELLULAR-CARCINOMA RISK; TERM ANTIVIRAL THERAPY; FIBROSIS; IMPROVEMENT; TIME;

D O I：

10.1016/j.cgh.2022.10.035

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BACKGROUND & AIMS: We investigated whether baseline and on-treatment alanine aminotransferase (ALT) levels during entecavir (ETV) therapy are associated with achieving subcirrhotic liver stiffness (LS) and hepatocellular carcinoma (HCC) development in patients with hepatitis B virus (HBV)- related cirrhosis.METHODS: We analyzed data from 347 treatment-naive patients with HBV-related cirrhosis, who started ETV between 2006 and 2011 and were followed up for >5 years without developing HCC. The study outcomes were achieving subcirrhotic LS at 5 years of ETV, and risk of HCC development beyond 5 years of ETV. Subcirrhotic LS was defined as <12 kPa by transient elastography.RESULTS: After 5 years of ETV, 227 (65.4%) patients achieved subcirrhotic LS. During a median follow-up of 9.2 years, 49 (14.1%) patients developed HCC beyond 5 years of ETV. ALT levels at baseline, at 1 year of ETV therapy, and 5 years of ETV therapy were not associated with the probability of achieving subcirrhotic LS at 5 years of ETV therapy or risk of HCC development beyond 5 years of ETV therapy (all P > .05). Patients achieving subcirrhotic LS at 5 years of ETV therapy had significantly lower risk of HCC development than those who did not (adjusted hazard ratio, 0.33; 95% confidence interval, 0.17-0.64; P 1/4 .001).CONCLUSIONS: Baseline and on-treatment ALT levels were not associated with achieving subcirrhotic LS at 5 years of ETV therapy or with risk of HCC development beyond 5 years of ETV therapy in patients with HBV-related cirrhosis. Achieving subcirrhotic LS at 5 years of ETV therapy was independently associated with lower risk of HCC development beyond 5 years of ETV therapy.

引用

页码：2278 / +

页数：15

共 34 条

[1] Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B [J].